bitcoin started, Top

Institution: The Swiss National Bank does not need to cut interest rates sharply again. Melanie Debono, a macroeconomic analyst at Pantheon, wrote in a report that the Swiss National Bank does not need to cut borrowing costs sharply again. Earlier, the Swiss National Bank unexpectedly cut interest rates by 50 basis points. Most analysts had expected a more cautious rate cut of 25 basis points. Debono said that there may be further relaxation after this move, but only a little. Pantheon Macroeconomics predicts that the Swiss National Bank will cut interest rates by 25 basis points again in March next year.Spot gold just broke through the $2,710.00/oz mark, and the latest price was $2,709.91/oz, down 0.29% in the day; COMEX gold futures main force recently reported $2,744.30 per ounce, down 0.45% in the day.HKEx: It is estimated that the T+1 settlement system will be ready by the end of 2025.

Guotai Junan: The long-term incremental "option" brought by humanoid robots is expected to help the valuation of the rare earth sector rise. When looking forward to the strategy of the rare earth sector in 2025, Guotai Junan said that the market had expected that with the slowdown in the growth of core demand power such as new energy vehicles and wind power in the future, the demand for rare earth markets is under downward pressure. However, we expect that the rising consumption of magnetic materials for new energy vehicles and the warming demand for wind power are still expected to support the basic demand growth, and the demand for equipment renewal that began to land in 2024 is expected to become a new driving force for rare earth demand. On the supply side, an orderly pattern of domestic supply has been established, with many overseas planning increments but slow actual volume, and continuous supply-side constraints. In addition, the long-term incremental "options" brought by humanoid robots are also expected to help the valuation of the plate rise.Yibin Paper: Terminate the issue of A shares to specific targets in 2022 and withdraw the application documents. Yibin Paper announced that the company held the 31st meeting of the 11th Board of Directors and the 22nd meeting of the 11th Board of Supervisors on December 12, 2024, and deliberated and passed the Proposal on Terminating the Issue of A shares to specific targets in 2022 and withdrawing the application documents. Considering the changes in market environment and policies, and considering the actual situation, the company decided to terminate the issuance of A shares to specific targets.Tiankang Bio: Tiankang Bio (002100) announced on the evening of December 12 that Tiankang Bio (stock code: 874339), a holding subsidiary of the company, intends to apply for public offering of shares to unspecified qualified investors and listing on the Beijing Stock Exchange. As of the disclosure date of the announcement, Tiankang Bio's public offering of shares to unspecified qualified investors and listing on the North Stock Exchange are under counseling.

Lu 'an Huaneng: The raw coal output in November was 5.09 million tons, down 5.39% year-on-year. Lu 'an Huaneng announced that the raw coal output in November 2024 was 5.09 million tons, down 5.39% year-on-year; The sales volume of commercial coal was 5.36 million tons, up 18.32% year-on-year. In 2024, the cumulative output of raw coal was 52.25 million tons, down 4.88% year-on-year; The cumulative sales volume of commercial coal was 47.09 million tons, down 4.48% year-on-year.CITIC Securities: The resonance between supply and demand of medical beauty accelerates the space expansion, and the difference in operating ability promotes the evolution of the industry structure. CITIC Securities Research Report stated that the medical beauty industry has both medical and consumption attributes, and the medical attribute has strong product-driven characteristics, while the consumption attribute has high operating ability requirements. The medical beauty botulinum toxin track is also affected by the dual attributes of medicine and consumption: 1) The increase in penetration rate, the acceleration of compliance substitution and the extension of indications have brought about high demand for medical beauty botulinum toxin, and with the recent supply expansion, the industry scale has experienced high growth; 2) The iteration of product innovation is slow, brand barriers are created through marketing, doctors are empowered through direct sales, and control is strengthened to enhance product competitiveness. Recently, a variety of medical botulinum toxins in China have been approved, and the promotion of low-priced products is expected to push up the penetration rate, and enterprises with strong operational capabilities will enter the market or promote the evolution of the pattern.